Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT00137774
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
  • Temozolomide — DRUG
    Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.

Study Details

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

Key Dates

First listed
Aug 30, 2005
Start date
Nov 30, 2004
Status verified
Apr 2013
Primary completion
Jul 31, 2005
Completion
Dec 31, 2012

Study Design

Enrollment
34 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To assess the response to bevacizumab in combination with temozolomide in patients with metastatic neuroendocrine tumors [ Time Frame: 2 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02115-
Dana-Farber Cancer InsituteBostonMassachusetts02115-
Massachusetts General HospitalBostonMassachusetts02115-

Find similar trials in Boston, MA

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Beth Israel Deaconess Medical Center· Boston, MADana-Farber Cancer Insitute· Boston, MAMassachusetts General Hospital· Boston, MA

Related Studies